Key result
MonoHER (1 mM) significantly protected neonatal rat cardiac myocytes against doxorubicin-induced cytotoxicity (P<0.004), whereas a 3.5-fold increase in catalase activity via gene transfer provided no protection.
Why the study?
Does catalase gene transfer or monoHER protect against doxorubicin-induced cardiotoxicity in cultured neonatal rat cardiac myocytes?
Does catalase gene transfer or monoHER protect against doxorubicin-induced cardiotoxicity in cultured neonatal rat cardiac myocytes?
p-value: p=<0.004
MonoHER effectively protects against doxorubicin-induced cardiotoxicity in vitro, whereas adenovirus-mediated catalase gene transfer is limited by vector toxicity at higher doses.
No takes yet. Share an insight, caveat, or question.
MonoHER merits in vivo testing as a doxorubicin cardioprotectant; leaves open whether catalase gene transfer can be optimized without vector toxicity.
Hassan et al. (2003) studied Doxorubicin-induced cardiotoxicity. Catalase gene therapy (AdCat) and Monohydroxyethylrutoside (MonoHER) vs. Doxorubicin alone was evaluated on Cell survival, LDH release, and beating rate (p=<0.004). MonoHER (1 mM) significantly protected neonatal rat cardiac myocytes against doxorubicin-induced cytotoxicity (P<0.004), whereas a 3.5-fold increase in catalase activity via gene transfer provided no protection.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: